|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Receivables from brokers, dealers, and clearing agencies | ||||||||||||||||||||
| Due from related party | ||||||||||||||||||||
| Other receivables | ||||||||||||||||||||
| Due From Related Parties | ||||||||||||||||||||
| Total other receivables | ||||||||||||||||||||
| Investments-trading | ||||||||||||||||||||
| Other Investments, Fair Value Disclosure | ||||||||||||||||||||
| Receivables under resale agreements | ||||||||||||||||||||
| Investments in equity method affiliates | ||||||||||||||||||||
| Deferred income taxes | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Right-of-use asset - operating leases | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Payables to brokers, dealers, and clearing agencies | ||||||||||||||||||||
| Accounts payable and other liabilities | ||||||||||||||||||||
| Due to related parties | ||||||||||||||||||||
| Accrued compensation | ||||||||||||||||||||
| Lease liability - operating leases | ||||||||||||||||||||
| Trading securities sold, not yet purchased | ||||||||||||||||||||
| Other investments sold, not yet purchased, at fair value | ||||||||||||||||||||
| Securities sold under agreements to repurchase | ||||||||||||||||||||
| Redeemable financial instruments | ||||||||||||||||||||
| Debt | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders' Equity: | ||||||||||||||||||||
| Voting Non-Convertible Preferred Stock, $0.001 par value per share, 50,000,000 shares authorized, 27,413,098 shares issued and outstanding | ||||||||||||||||||||
| Common Stock, $0.01 par value per share, 100,000,000 shares authorized, 3,228,970 and 2,130,063 shares issued and outstanding, respectively, including 589,137 and 380,008 unvested or restricted share awards, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Non-controlling interest | ||||||||||||||||||||
| Total equity | ||||||||||||||||||||
| Total liabilities and equity |
Loading...
